All In MedTech

FDA Clearance Tracker · P980016-S555

EVERA MRI XT DR/VR SURESCAN,EVERA MRI S DR/VR SURESCAN ICDS AND PROGRAMMER SOFTWARE

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Apr 28, 2016 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Apr 28, 2016

Approved

Time to decision

198 days

Received Oct 13, 2015. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P980016-S555
Device name
EVERA MRI XT DR/VR SURESCAN,EVERA MRI S DR/VR SURESCAN ICDS AND PROGRAMMER SOFTWARE
Applicant location
Mounds View, MN
Received
Oct 13, 2015
Decided
Apr 28, 2016
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P980016

Device type

Device class
Class III

Every decision under product code LWS

FDA's approval statement

As written in FDA's record.

Approval for the expansion of MRI conditional labeling for the Advisa and Evera SureScan Systems to 3T MRI.

Source documents

Other decisions for Medtronic Cardiac Rhythm Disease Management

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.